BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 8, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

April 8, 2004

View Archived Issues

Hypolipidemic effects of GW-707 occur via disruption of intracellular sterol trafficking

Read More

CETP and HDL: potential targets for the prevention of cardiovascular disease

Read More

Vardenafil improves erection and depression in patients with erectile dysfunction

Read More

Shire acquires U.K., Ireland marketing rights for Reminyl

Read More

Chiesi and Novartis enter Italian agreement for HFA Formoterol pMDI

Read More

Trials with Guidant's two everolimus-eluting stents begin and complete enrollment

Read More

NCI grant supports development of multiepitope cancer vaccine at Epimmune

Read More

SBIR grant funds development of discodermolide analogue production

Read More

Series C financing at Salmedix will fund pipeline progression

Read More

Screening acceptance letter for open-label extension study of Tectin

Read More

BioCurex Serum-RECAF test detects 90% of lung cancer in study

Read More

Ovation acquires North American rights for Sabril and Frisium from Aventis

Read More

Novel TNF-alpha inhibitors presented by Procter & Gamble

Read More

Lilly describes novel potent and selective 5-HT1F receptor agonists

Read More

BAY-43-9006 receives fast track status

Read More

Phase II trial of FM-VP4 meets primary endpoint

Read More

Development of NeuroVax supported by ITN grant

Read More

Pivotal phase III trial studies teduglutide for short bowel syndrome

Read More

Abbott completes acquisition of TheraSense

Read More

Remicade sBLA accepted for first-line use in early RA

Read More

BN-82002, a Cdc25 phosphatase inhibitor, supports possible target for cancer treatment

Read More

University of Pittsburgh discovers competitive Cdc25B inhibitor

Read More

Abbott's A-382535 demonstrates antiproliferative and apoptotic effects in human cancer cell lines

Read More

New antibacterial ketolides developed at Enanta

Read More

New modulators of nAchR and/or monoamine transporters claimed by NeuroSearch

Read More

Quinoline-based PARP inhibitors newly discovered at Kyorin

Read More

Novel beta2-adrenoceptor agonists and their use in respiratory disorders

Read More

New HIV protease inhibitors designed by Tibotec scientists

Read More

New prodrugs of beta-lactamase inhibitors covered by Pfizer patent

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 5, 2025.
  • Mesothelin is biomarker, potential target in arthritic bone damage

    BioWorld Science
    In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing